Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 Infected, Treatment-experienced Subjects With Drug-resistant Virus or an Observational Study.

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00123890

Enrollment

Registered

2005-07-26

Start date

2005-06-30

Completion date

2005-10-31

Last updated

2011-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infection

Keywords

HIV-1 GW873140 CCR5 antagonist experienced

Brief summary

The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.

Interventions

DRUGGW873140

Study design

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* HIV-infected. * Screening viral load at least 5000copies/mL. * Total prior antiretroviral experience of at least 3 months and documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI), stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening. * Able to receive a ritonavir-boosted protease inhibitor during treatment studies. * Women of childbearing potential must use specific forms of contraception.

Exclusion criteria

* Acute laboratory abnormalities. * History of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any chronic liver disease. Screening liver function tests will be used to determine eligibility. * Changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of treatment or observational studies. * Pregnancy or breastfeeding women. * Recent participation in an experimental drug trial. * Prior use of a CCR5 or CXCR4 antagonist. * Significant ECG abnormalities or significant history of active pancreatitis, hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe illness. * Current use of certain medications may exclude participation in this study. * Additional qualifying criteria and laboratory test requirements to be assessed by study physician.

Design outcomes

Primary

Measure	Time frame
Determination of subject eligibility for CCR102709, CCR104456, CCR104458, or CCR104629.	—

Countries

Belgium, Canada, Denmark, Germany, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026